[go: up one dir, main page]

AR035039A1 - COMPOSICIONES QUE COMPRENDEN COMPONENTES TERAPEeTICAMENTE ACTIVOS DE SOLUBILIDAD Y BIODISPONIBILIDAD INCREMENTADA - Google Patents

COMPOSICIONES QUE COMPRENDEN COMPONENTES TERAPEeTICAMENTE ACTIVOS DE SOLUBILIDAD Y BIODISPONIBILIDAD INCREMENTADA

Info

Publication number
AR035039A1
AR035039A1 ARP010103345A ARP010103345A AR035039A1 AR 035039 A1 AR035039 A1 AR 035039A1 AR P010103345 A ARP010103345 A AR P010103345A AR P010103345 A ARP010103345 A AR P010103345A AR 035039 A1 AR035039 A1 AR 035039A1
Authority
AR
Argentina
Prior art keywords
component
solubility
compositions
components
therapeutically active
Prior art date
Application number
ARP010103345A
Other languages
English (en)
Original Assignee
Allergan Sales Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22814167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR035039(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Sales Inc filed Critical Allergan Sales Inc
Publication of AR035039A1 publication Critical patent/AR035039A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones de componentes terapéuticamente activos (CTAs) de solubilidad incrementada, indistintamente en el sistema biológico y/o en el entorno o zona del medio donde dichos componentes, diferentes de las ciclodextrinas, son administrables sin degradación sustancial de su actividad. Composiciones que comprenden cantidades efectivas de componente(s) terapéuticamente activo(s) que proporcionan en los pacientes respuestas terapéuticas deseables, caracterizadas porque comprenden: un componente de aumento de la solubilidad diferente de la ciclodextrina, en cantidades efectivas para aumentar la solubilidad del componente terapéuticamente activo en la composición con respecto a la solubilidad de un componente terapéuticamente activo idéntico en composiciones similares sin el componente que incrementa la solubilidad. Un componente de oxi-cloro en una cantidad efectiva que por lo menos ayude a conservar la composición; y un componente de vehículo líquido. Dicho componente activo es preferentemente elegido entre los agonistas adrenérgicos, como por ejemplo imidazolinas, iminoimidazolinas, imidazoles, azepinas, tiazinas, oxazolinas, guanidinas, catecolaminas, derivados de las mismas y mezclas de las mismas, inclusive compuestos de quinoxalina y componentes polianiónicos, tal como polímeros derivados de ácidos algínicos,derivados de polímeros aniónicos derivados aminoácidos y mezclas de los mismos.
ARP010103345A 2000-07-14 2001-07-13 COMPOSICIONES QUE COMPRENDEN COMPONENTES TERAPEeTICAMENTE ACTIVOS DE SOLUBILIDAD Y BIODISPONIBILIDAD INCREMENTADA AR035039A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21820600P 2000-07-14 2000-07-14

Publications (1)

Publication Number Publication Date
AR035039A1 true AR035039A1 (es) 2004-04-14

Family

ID=22814167

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103345A AR035039A1 (es) 2000-07-14 2001-07-13 COMPOSICIONES QUE COMPRENDEN COMPONENTES TERAPEeTICAMENTE ACTIVOS DE SOLUBILIDAD Y BIODISPONIBILIDAD INCREMENTADA

Country Status (23)

Country Link
US (2) US6562873B2 (es)
EP (2) EP2153819B1 (es)
JP (1) JP2004503593A (es)
KR (1) KR20030023700A (es)
CN (1) CN1441679A (es)
AR (1) AR035039A1 (es)
AU (2) AU2001273268B2 (es)
BR (1) BR0112461A (es)
CA (1) CA2416169C (es)
CY (1) CY1113391T1 (es)
DK (1) DK2153819T3 (es)
ES (1) ES2392636T3 (es)
HU (1) HU230383B1 (es)
IL (2) IL153322A0 (es)
MX (1) MXPA02012206A (es)
NO (1) NO331816B1 (es)
NZ (1) NZ522610A (es)
PL (1) PL361027A1 (es)
PT (1) PT2153819E (es)
RU (1) RU2291685C2 (es)
TW (1) TWI287992B (es)
WO (1) WO2002005822A2 (es)
ZA (1) ZA200209877B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL360707A1 (en) * 2000-07-14 2004-09-20 Allergan Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
KR20030023700A (ko) * 2000-07-14 2003-03-19 알러간, 인코포레이티드 치료활성 성분을 함유하고 용해도가 증강된 조성물
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050282774A1 (en) * 2000-10-31 2005-12-22 Eek Bjorn C Method and pharmaceutical to treat spinal discs
US20030114460A1 (en) * 2001-12-14 2003-06-19 Allergan Sales, Inc. Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US6982079B2 (en) * 2002-04-26 2006-01-03 Allergan, Inc. Compositions for treating hyperemia
JP2006504661A (ja) 2002-07-30 2006-02-09 オメロス コーポレイション 眼科学的洗浄溶液および眼科学的洗浄方法
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7022740B2 (en) * 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
ES2393675T3 (es) * 2005-07-13 2012-12-27 Santen Pharmaceutical Co., Ltd. Composición conservante para uso oftálmico
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
EP2279005A1 (en) * 2008-05-19 2011-02-02 Alcon Research, Ltd. Pharmaceutical compositions having carboxyvinyl polymer and povidone polymer
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20110244058A1 (en) * 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
SI2320911T1 (sl) * 2008-08-01 2014-12-31 Eye Therapies Llc Vazokonstrikcijski sestavki in metode uporabe
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
WO2011075621A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
CA2794956C (en) 2010-04-03 2017-05-02 Praful Doshi Medical devices including medicaments and methods of making and using same
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
CA2796041A1 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservative compositions for ophthalmic formulations
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
EP2621281A1 (de) 2010-10-01 2013-08-07 Elektra Management s.r.o. Lösung von guanidinium-verbindungen, verfahren unter einsatz dieser lösung sowie deren verwendung
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
CN104114152A (zh) 2011-12-07 2014-10-22 阿勒根公司 用盐敏性乳液体系对人泪液膜进行有效脂质递送
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ES2575676T3 (es) * 2012-01-20 2016-06-30 Aratana Therapeutics Nv Composición de colirio
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
ES2818073T3 (es) 2013-12-24 2021-04-09 Sentiss Pharma Private Ltd Solución oftálmica de tartrato de brimonidina tópica
KR102487299B1 (ko) 2014-11-25 2023-01-10 알러간, 인코포레이티드 안정화된 오메가-3 안과용 조성물
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
EP4420726A3 (en) * 2015-03-19 2024-11-13 Allergan, Inc. Fixed dose combination of bromonidine and timolol
US11242367B2 (en) 2016-08-12 2022-02-08 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
SG11201910085UA (en) * 2017-05-11 2019-11-28 Nevakar Inc Atropine pharmaceutical compositions
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
WO2021220194A1 (en) 2020-04-29 2021-11-04 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of brinzolamide and brimonidine
GR1010024B (el) * 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
JP7792756B2 (ja) * 2020-05-20 2025-12-26 千寿製薬株式会社 ブリモニジンを含有する液体製剤
JP2022123792A (ja) * 2021-02-12 2022-08-24 参天製薬株式会社 水性医薬組成物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154119B (de) * 1961-11-30 1963-09-12 Boehringer Sohn Ingelheim Verfahren zur Herstellung von 2-(2', 4', 6'-Trimethylbenzyl)-1, 3-diazacyclopenten-(2) und seinen Salzen
US3278447A (en) * 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
JPS542338A (en) * 1977-04-22 1979-01-09 Sandoz Ag Pharmaceutical composition
US4474787A (en) 1977-05-04 1984-10-02 Fisons Limited 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4530920A (en) 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4806556A (en) 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
CA2007181C (en) 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5352796A (en) 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
GB9017353D0 (en) 1990-08-08 1990-09-19 Merck Sharp & Dohme Chemical process
RU2079304C1 (ru) * 1990-11-08 1997-05-20 Фудзисава Фармасьютикал Ко., Лтд. Фармацевтическая композиция, обладающая иммуносупрессорной и антимикробной активностями
DK0643581T3 (da) 1992-04-21 2000-04-25 Schepens Eye Res Inst Okulær androgenbehandling ved Sjögren's syndrom
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
AU6124494A (en) 1993-01-28 1994-08-15 University Of Iowa Research Foundation, The Ophthalmic uses of signa agonists
CA2173974C (en) 1993-10-13 2006-05-02 James A. Burke Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5994110A (en) 1995-02-10 1999-11-30 Mosbach; Klaus Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
ZA965837B (en) 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
US5952345A (en) 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
EP0834308A1 (en) 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
EP0975607A1 (en) 1997-04-18 2000-02-02 Abbott Laboratories A process for the preparation of highly pure 6,7-dichloro-5- nitro-2,3-dihydroquinoxaline-2,3-dione
WO1999043299A2 (en) 1998-02-26 1999-09-02 Abbott Laboratories Oral formulation for hydrophilic drugs
ES2203103T3 (es) 1998-04-07 2004-04-01 Alcon Manufacturing Ltd. Composiciones oftalmicas gelificantes que contienen goma xantana.
AU757896B2 (en) * 1998-09-02 2003-03-13 Allergan, Inc. Preserved cyclodextrin-containing compositions
AU6416999A (en) * 1998-10-08 2000-04-26 Hampar L. Karagoezian Synergistic antimicrobial, dermatological and ophthalmic preparations containingchlorite and hydrogen peroxide
US6514504B1 (en) * 1999-08-18 2003-02-04 The Procter & Gamble Company Discontinuous films from skin care compositions
PL360707A1 (en) * 2000-07-14 2004-09-20 Allergan Inc. Compositions containing alpha-2-adrenergic agonist components
KR20030023700A (ko) * 2000-07-14 2003-03-19 알러간, 인코포레이티드 치료활성 성분을 함유하고 용해도가 증강된 조성물

Also Published As

Publication number Publication date
KR20030023700A (ko) 2003-03-19
NO331816B1 (no) 2012-04-10
JP2004503593A (ja) 2004-02-05
HUP0301405A3 (en) 2006-02-28
US20030153530A1 (en) 2003-08-14
PL361027A1 (en) 2004-09-20
AU2001273268B2 (en) 2005-08-25
EP2153819B1 (en) 2012-09-05
IL153322A0 (en) 2003-07-06
NO20030153D0 (no) 2003-01-13
WO2002005822A2 (en) 2002-01-24
BR0112461A (pt) 2003-07-22
NO20030153L (no) 2003-01-13
NZ522610A (en) 2004-11-26
ES2392636T3 (es) 2012-12-12
EP1301210A2 (en) 2003-04-16
ZA200209877B (en) 2003-09-29
EP2153819A3 (en) 2010-05-12
CY1113391T1 (el) 2016-06-22
US6562873B2 (en) 2003-05-13
HUP0301405A2 (hu) 2003-08-28
AU7326801A (en) 2002-01-30
RU2291685C2 (ru) 2007-01-20
HU230383B1 (hu) 2016-03-29
DK2153819T3 (da) 2012-12-03
IL153322A (en) 2011-01-31
EP2153819A2 (en) 2010-02-17
TWI287992B (en) 2007-10-11
CA2416169A1 (en) 2002-01-24
US20020071874A1 (en) 2002-06-13
CA2416169C (en) 2008-09-23
WO2002005822A3 (en) 2002-05-02
MXPA02012206A (es) 2003-06-04
PT2153819E (pt) 2012-11-14
CN1441679A (zh) 2003-09-10

Similar Documents

Publication Publication Date Title
AR035039A1 (es) COMPOSICIONES QUE COMPRENDEN COMPONENTES TERAPEeTICAMENTE ACTIVOS DE SOLUBILIDAD Y BIODISPONIBILIDAD INCREMENTADA
AU2012318331B2 (en) Antimicrobial compositions and methods employing same
BR112014000876A2 (pt) composições em gel de oximetazolina e métodos de uso
BR0312141A (pt) Pastas veterinárias homogêneas orais anti-helmìnticas
GB2480772A (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
BR112017023380A2 (pt) sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo.
BRPI0711380A2 (pt) hidrogéis de misturas de polissacarídeos para engenharia de tecido e como veículos de compostos ativos
BRPI0412054A (pt) preparação farmacêutica transdérmica
AR035550A1 (es) Composiciones estables biocidas
MA29851B1 (fr) Composes et compositions contenant de la diarylamine et utilisation en tant que modulateurs de recepteurs de c-kit
AR062046A1 (es) Soluciones oftalmicas
BR112017006526A2 (pt) composição e kits para inibição de infecção microbiana patogênica e métodos de usar os mesmos
BRPI0306993B8 (pt) polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
BRPI0819719B8 (pt) compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
CO5440227A1 (es) Composicion antihelmitica e inyectable mejorada de crecimiento
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BRPI0512062A (pt) processo para desencolar e lavar simultaneamente tecido encolado contendo amido ou derivados de amido, composição, e, uso da mesma
BRPI0612125A2 (pt) compostos da fórmula (i), processo para a fabricação destes, composto da fórmula iiia, composições farmacêuticas, método para o tratamento e/ou profilaxia de doenças associadas à modulação dos receptores cb1 e uso de compostos
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
BRPI0408827A (pt) composições oftálmicas preservadas
ES2183359T3 (es) Agente desinfectante de pezones por inmersion.
BRPI0413413A (pt) feniloxazolidinonas de piperidino substituìdo tendo atividade antimicrobiana com eficácia in vivo melhorada
CO2022003346A2 (es) Composiciones de recubrimiento de semillas

Legal Events

Date Code Title Description
FC Refusal